leadXpro & Partex.AI: Collaboration to expand indications and support out-licensing of A2BR antagonist program

Under the agreement, Partex will apply its proprietary AI platform to identify and prioritize new therapeutic indications beyond LeadXpro’s current development focus and support the identification of potential licensing partners and downstream partnering activities. leadXpro will continue to lead research and preclinical development, contributing its expertise in medicinal chemistry and translational drug development. Dr. Frank Grams, Chief Commercial Officer of Partex, noted that the collaboration reflects Partex’s commitment to expanding the value of promising assets by combining data-driven insights with its global partnering network to support future licensing opportunities.

A2BR antagonists are a well-validated therapeutic class with applications across immunooncology, inflammation, and central nervous system disorders. By combining LeadXpro’s discovery know-how with Partex’s analytical and partnering capabilities, the collaboration aims to accelerate strategic decision-making, refine indication positioning, and efficiently advance partnering opportunities. Dr. Michael Hennig, Chief Executive Officer of leadXpro, added that Partex brings strong analytical capabilities and transaction experience that support leadXpro’s efforts to explore new indications and position the program for future partnering, while allowing the company to remain focused on advancing the science.